The global clinical trial landscape of PD-1-containing bispecific antibodies for gastric cancer: current status and future directions of targeting immune tolerance
Gastric cancer (GC) remains a leading cause of cancer-related death worldwide, and PD-1 monotherapy offers limited clinical benefit due to intrinsic and acquired immune tolerance. PD-1-containing bispecific antibodies (BsAbs) represent an emerging immu…